Strides develops and commences export of favipiravir antiviral tablets
Indian drugmaker Strides Pharma Science (BSE: 532531) today announced that it has developed and commercialized favipiravir antiviral tablets, with the company’s shares jumping 13.4% to 425.00 rupees on the news.
The product is a generic version of Avigan of Japan’s Toyama Chemical. Favipiravir is an antiviral medication that was initially developed to treat influenza in Japan. In February 2020, post the outbreak of novel coronavirus (COVI-19), favipiravir was studied in China and several other countries as an experimental treatment of COVID-19. The drug has demonstrated positive outcomes, including a reduction in the duration of COVID-19 and improved lung conditions for the patients.
Strides has developed favipiravir tablets in 400mg and 200mg strengths for convenient dosage administration. The product is currently being exported to GCC countries to treat patients under their treatment program for COVID-19.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze